The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the company announced. News News CME CME ...

The Food and Drug Administration (FDA) has approved pharmaceutical company Merck’s (NYSE:MRK) new vaccine, Capvaxive. This pneumococcal conjugate vaccine is designed to prevent invasive disease ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia.

FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease Provided by Dow Jones Jun 17, 2024, 10:05:00 PM. By Emon Reiser . The Food and Drug Administration approved Merck's Capvaxive ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, ... US FDA approves Merck's pneumococcal vaccine for adults. June 17, 2024 at 5:52 PM.